Phase I Dose-Escalation Study of MEDI-573, a Bispecific,...

Clinical Cancer Research 2014 / 09 Vol. 20; Iss. 18

Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

Haluska, P., Menefee, M., Plimack, E. R., Rosenberg, J., Northfelt, D., LaVallee, T., Shi, L., Yu, X.-Q., Burke, P., Huang, J., Viner, J., McDevitt, J., LoRusso, P.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
20
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.ccr-14-0114
Date:
September, 2014
File:
PDF, 422 KB
english, 2014
Conversion to is in progress
Conversion to is failed